Day One Biopharmaceuticals (DAWN) 10-K 2024 FY Annual report

Exhibit 23.2

CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statements (Form S-8 Nos. 333-284210, 333-256521, 333-263343, 333-268071, 333-269727and 333-276372) pertaining to the 2021 Equity Incentive Plan, 2021 Employee Stock Purchase Plan and 2022 Equity Inducement Plan of Day One Biopharmaceuticals, Inc., and

(2)

Registration Statements (Form S-3 Nos. 333-281822, 333-265346 and 333-274521) of Day One Biopharmaceuticals, Inc.

of our report dated March 6, 2023, with respect to the financial statements of Day One Biopharmaceuticals, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2024.

/s/ Ernst & Young LLP

San Mateo, California

February 25, 2025